On this page
CAG/GLP-1: Research Blend Profile
CAG/GLP-1 is not one molecule but a paired formulation, which makes it a formulation-level research object rather than a single compound. The interest is what happens when two mechanistically separate receptor systems are engaged in the same preparation. This profile covers what the blend contains, what each constituent contributes, and why the two pathways are studied side by side. For the wider grouping, the metabolic peptides overview is the class hub.
What is CAG/GLP-1?#
CAG/GLP-1 is a multi-compound research formulation that combines two peptides from adjacent corners of the metabolic class. The "CAG" arm is an amylin-family receptor-signaling peptide; the "GLP-1" arm is a peptide studied for its interaction with the glucagon-like peptide-1 receptor. The two act on separate receptor systems, so the formulation is characterized less by a single mass or sequence and more by the pair of pathways it engages: amylin and calcitonin receptor coupling on one side, incretin-family G-protein-coupled receptor signaling on the other. That pairing is the reliable identity anchor for a blend of this kind.
| Attribute | Value |
|---|---|
| Common name | CAG/GLP-1 (dual-pathway research blend) |
| Class | Two-peptide metabolic research formulation |
| Amylin arm ("CAG") | Amylin-family receptor-signaling peptide — amylin (AMY1/2/3) and calcitonin receptor complexes |
| Incretin arm ("GLP-1") | GLP-1 receptor-pathway peptide — GLP-1 receptor (GLP1R), UniProt P43220, a class B GPCR |
| Native incretin ligand source | Proglucagon (GCG) — UniProt P01275 |
| Study frame | Co-activation of two independent receptor systems in one preparation |
What does each constituent contribute?#
The amylin arm is studied for activity at brainstem amylin and calcitonin receptor complexes, where animal-model work reports that a long-acting amylin analog acts through amylin receptors AMY1R and AMY3R, the receptor mechanism the amylin literature turns on. The incretin arm is studied for how it binds the GLP-1 receptor, a class B G-protein-coupled receptor annotated at UniProt P43220, and drives cAMP and other second-messenger cascades. Each arm has its own dedicated profile: the Cagrilintide amylin analog and the GLP-1 incretin-pathway peptide. This is preclinical receptor pharmacology and does not describe effects in people.
Why are the two pathways studied together?#
The amylin and incretin systems are independent: one signals through amylin and calcitonin receptor complexes, the other through the GLP-1 receptor. Because they do not overlap, the pharmacology literature examines them both individually and, in dual-pathway preparations, together, asking how a single formulation engaging two receptor systems compares against each single-receptor baseline. Research on CAG/GLP-1 as a preparation is conducted in cell-based receptor and functional binding assays and in rodent in-vivo models. It is preclinical, mechanism-focused work, and it does not establish outcomes in people.
Where CAG/GLP-1 sits among the metabolic peptides#
CAG/GLP-1 folds two members of the metabolic class into one preparation. Its incretin arm shares the receptor that the triple agonist GLP-3 engages, though GLP-3 also acts at the GIP and glucagon receptors, and its amylin arm acts on the separate receptor system detailed in the Cagrilintide profile. The three appear across overlapping energy-balance research yet reach it by different receptors, a distinction the metabolic peptides overview maps in full.
Handling and storage#
CAG/GLP-1 is supplied as a lyophilized powder for reconstitution and, as a two-peptide preparation, is handled with the standard catalog care. The reconstitution primer covers solvent choice and aggregation, and the cold-chain article covers how stability changes once the powder is in solution. Lyophilized material is typically held at -20°C protected from light, and freeze-thaw cycling is minimized once reconstituted.
Frequently asked
- What is CAG/GLP-1?
- CAG/GLP-1 is a multi-compound research formulation that pairs an amylin-family receptor-signaling peptide with a GLP-1 receptor-pathway peptide. It is studied as a single preparation for co-activation of two independent receptor systems in cell-based and rodent preclinical models. It is a laboratory research compound and is not for human use.
- Which receptor systems does the blend engage?
- Two separate ones. The amylin arm is studied at amylin (AMY1/2/3) and calcitonin receptor complexes; the incretin arm is studied at the GLP-1 receptor (GLP1R, UniProt P43220), a class B G-protein-coupled receptor whose native ligand is cleaved from proglucagon (GCG, UniProt P01275). The two pathways are independent, which is why they are researched together in one preparation.
- How does CAG/GLP-1 relate to its individual constituents?
- It is the two constituents supplied as one preparation. The amylin arm has its own Cagrilintide compound profile and the incretin arm has its own GLP-1 compound profile, which cover each mechanism in depth. This blend profile stays at the formulation level: what the pair contains and why the two receptor systems are studied side by side.
Sources and further reading#
- GLP-1 receptor (GLP1R), UniProt P43220: canonical annotation for the class B GPCR engaged by the incretin arm.
- Proglucagon (GCG), UniProt P01275: the precursor from which the native GLP-1 ligand is cleaved.
- A long-acting amylin analog acts through brain amylin receptors AMY1R and AMY3R (PMC12270663): receptor-mechanism study for the amylin-family arm in animal models.
Last updated: 2026-08-17